Chunxiao Zhou

ORCID: 0000-0002-1257-9537 · 6 papers in corpus
review 2025
Frontiers in pharmacology ·doi:10.3389/fphar.2025.1702273

Ovarian cancer, particularly epithelial ovarian cancer (EOC), is the most aggressive and lethal gynecologic malignancy, necessitating the development of innovative and potent therapies to improve its prognosis. Human polo-like kinase 1 (PLK…

lab-animal 2025
Frontiers in pharmacology ·doi:10.3389/fphar.2025.1520771

OBJECTIVE: Chronic inflammation is a key contributor to carcinogenesis, progression, and chemoresistance in ovarian cancer, making inflammatory pathways a logical therapeutic target for the treatment of this disease. Sulindac, a commonly us…

other 2023
International journal of medical sciences ·doi:10.7150/ijms.79516

Endometriosis is a hormone-dependent disease in women of reproductive age and seriously affects women's health. To analyze the involvement of sex hormone receptors in endometriosis development, we performed bioinformatics analysis using fou…

case-report 2016
BMC cancer ·doi:10.1186/s12885-015-2045-8

BACKGROUND: Intravenous leiomyomas are a rare variant of uterine leiomyoma. Although histologically benign, these tumors are associated with a poor prognosis due to propensity for metastasis, high recurrence rate, difficulty of obtaining co…

case-report 2016
·doi:10.6084/m9.figshare.c.3599156

Abstract Background Intravenous leiomyomas are a rare variant of uterine leiomyoma. Although histologically benign, these tumors are associated with a poor prognosis due to propensity for metastasis, high recurrence rate, difficulty of obta…

case-report 2016
·doi:10.6084/m9.figshare.c.3599156.v1

Abstract Background Intravenous leiomyomas are a rare variant of uterine leiomyoma. Although histologically benign, these tumors are associated with a poor prognosis due to propensity for metastasis, high recurrence rate, difficulty of obta…